Pfizer, BioNTech Share Clinical Data Linking Favored COVID-19 Vaccine to Improved Tolerability-Fierce Biotech

Pfizer and BioNTech have published clinical data on the COVID-19 vaccine they advanced into phase 3. The early clinical data link the phase 3 candidate to a far lower rate of adverse events than another prospect, explaining Pfizer and BioNTech’s decision to move it into late-stage testing. Fierce Biotech, 08/21/2020

•   Print
•   Email
•   Share
•   Tweet